Acepodia secures FDA clearance to begin Phase I ACE723 trial

Acepodia has secured FDA clearance for an IND application for ACE723, allowing it to begin a Phase I trial in patients with unresectable or metastatic HCC. ACE723 was created using Acepodia's Antibody-Dual-Drugs Conjugation platform. The trial will involve patients with unresectable or metastatic hepatocellular carcinoma. Credit: MY STOCKERS / Shutterstock.com. Acepodia has secured the US Food and Drug Administration (FDA) clearance of an investigational new drug (IND) application for ACE723, allowing it to begin a Phase I clinical trial in patients with unresectable or metastatic hepatocellular carcinoma (HCC). ACE723 is an investigational antibody-drug conjugate (ADC) that targets glypican-3 (GPC3). LOA…

Source: Clinical Trials Arena